ASMB

About ASMB

Assembly Biosciences, Inc. is a clinical-stage biotechnology company engaged in the development of small molecule antiviral therapeutics. Its hepatitis B virus (HBV) pipeline includes potent, HBV core inhibitors in clinical development, which are designed to disrupt the virus replication cycle at several key points with a focus on achieving finite treatment and functional cures. Its HBV and hepatitis delta virus (HDV) pipeline also includes two complementary approaches: a viral entry inhibitor and an oral, liver-focused, interferon-alpha receptor agonist, with potential application for both HBV and as chronic suppressive therapy for HDV, which is associated with increased disease burden for HBV/HDV patients. The herpesvirus pipeline addresses two serious consequences associated with herpesvirus infections, high-recurrence genital herpes and transplant-associated herpesviruses. Its HBV and HDV programs include ABI-4334 (4334), ABI-5366 (5366), HBV/HDV inhibitor program, and others.